United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin sulfate 250 mg - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs, paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin sulfate is indicated for intestinal amebiasis—acute and chronic (note—it is not effective in extraintestinal amebiasis); management of hepatic coma—as adjunctive therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin 250 mg - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs, paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

central texas community health centers - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin 250 mg - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs, paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) -

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - paromomycin sulfate (unii: 845nu6gjps) (paromomycin sulfate - unii:845nu6gjps) -

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - paromomycin sulfate (unii: 845nu6gjps) (paromomycin sulfate - unii:845nu6gjps) -

United States - English - NLM (National Library of Medicine)

evereen shanghai biotechnology ltd. - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) -

United States - English - NLM (National Library of Medicine)

woodward pharma services llc - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of humatin™ capsules and other antibacterial drugs, humatin™ capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

waylis therapeutics llc - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of humatin™ capsules and other antibacterial drugs, humatin™ capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.